OLIARO BOSSO, Simonetta

OLIARO BOSSO, Simonetta  

SCIENZA E TECNOLOGIA DEL FARMACO  

Mostra records
Risultati 1 - 20 di 98 (tempo di esecuzione: 0.027 secondi).
Titolo Data di pubblicazione Autore(i) File
4-methyl zymosterone and other 4-methyl intermediates of sterol biosynthesis from yeast mutants engineered in the ERG27 gene encoding 3-ketosteroid reductase 2015 Ferrante, Terenzio; Barge, Alessandro; Albezzano, Claudia; Ballestrazzi Clara; Balliano, Gianni; Oliaro-Bosso, Simonetta
4-Methylzymosterone and Other Intermediates of Sterol Biosynthesis from Yeast Mutants Engineered in the ERG27 Gene Encoding 3-Ketosteroid Reductase 2016 Ferrante, T; Barge, A; Taramino, S; Oliaro-Bosso, S; Balliano, G
A mutation in yeast oxidosqualene cyclase (Erg7) makes it independent of 3-ketoreductase activity (Erg27) 2012 Layer Jacob V; Barnes Brett M; Yamasaki Yuji; Barbuch Robert; Li Lingtao; Taramino Silvia; Oliaro-Bosso Simonetta; Balliano Gianni; Bard Martin
A new bevacizumab carrier for intravitreal administration: Focus on stability 2021 Chirio D.; Peira E.; Sapino S.; Chindamo G.; Oliaro-bosso S.; Adinolfi S.; Dianzani C.; Baratta F.; Gallarate M.
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer 2023 Chiara Vigato, Agnese Chiara Pippione, Stefano Sainas, Iole Mannella, Laura Bertarini, Sandra Kovachka, Barbara Rolando, Osman Asghar Mirza, Karla Frydenvang, Francesca Spyrakis, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi
Access of the substrate to the active site of squalene and oxidosqualene cyclases: comparative inhibition, site-directed mutagenesis and homology-modelling studies. 2005 S. OLIARO-BOSSO; T. SCHULZ-GASCH; S. TARAMINO; M. SCALDAFERRI; F. VIOLA; G. BALLIANO
Access of the substrate to the active site of yeast oxidosqualene cyclase: a modelling and site-directed mutagenesis approach 2009 S. Oliaro-Bosso; S. Taramino; Y. Ferrari; G. Ermondi; G. Caron; F. Viola; G. Balliano
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis appoach. 2004 OLIARO-BOSSO S.; SCALDAFERRI M.; TARAMINO S.; F. VIOLA; G. BALLIANO
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach. 2005 Balliano G.; Oliaro-Bosso S.; Taramino S.; Viola F
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach. 2005 S. OLIARO-BOSSO; T. SCHULZ-GASCH; G. BALLIANO; F. VIOLA.
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors 2021 Peraldo-Neia C.; Ostano P.; Mello-Grand M.; Guana F.; Gregnanin I.; Boschi D.; Oliaro-Bosso S.; Pippione A.C.; Carenzo A.; De Cecco L.; Cavalieri S.; Micali A.; Perrone F.; Averono G.; Bagnasacco P.; Dosdegani R.; Masini L.; Krengli M.; Aluffi-Valletti P.; Valente G.; Chiorino G.
Aminopropylindenes derived from Grundmann’s ketone as a novel chemotype of oxidosqualene cyclase inhibitors. 2013 S. Lange; M. Keller; C. Müller; S. Oliaro-Bosso;G. Balliano; F. Bracher
Analogs of squalene and oxidosqualene inhibit oxidosqualene cyclase of Trypanosoma cruzi expressed in Saccharomyces cerevisiae 2005 Oliaro Bosso S.; Ceruti M.; Balliano G.; Milla P.; Rocco F.; Viola F.
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention 2017 Pippione, Agnese C.; Boschi, Donatella; Pors, Klaus; Oliaro-Bosso, Simonetta; Lolli, Marco L.
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 2019 Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro Bosso, Marco Lucio Lolli, Donatella Boschi
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 2019 Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi
Arylpiperidines as a new class of oxidosqualene cyclase inhibitors 2016 Keller, M.; Wolfgardt, A.; Müller, C.; Wilcken, R.; Böckler, F.M.; Oliaro-Bosso, S.; Ferrante, T.; Balliano, G.; Bracher, F.
Assessment of in‐situ gelling microemulsion systems upon temperature and dilution condition for corneal delivery of bevacizumab 2021 Peira E.; Chindamo G.; Chirio D.; Sapino S.; Oliaro-bosso S.; Rebba E.; Ivanchenko P.; Gallarate M.
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3 2019 Lolli, Marco L; Carnovale, Irene M; Pippione, Agnese C; Wahlgren, Weixiao Y; Bonanni, Davide; Marini, Elisabetta; Zonari, Daniele; Gallicchio, Margherita; Boscaro, Valentina; Goyal, Parveen; Friemann, Rosmarie; Rolando, Barbara; Bagnati, Renzo; Adinolfi, Salvatore; Oliaro-Bosso, Simonetta; Boschi, Donatella
Cannabinoid Delivery Systems for Pain and Inflammation Treatment 2018 Bruni, Natascia; Della Pepa, Carlo; Oliaro-Bosso, Simonetta; Pessione, Enrica; Gastaldi, Daniela; Dosio, Franco